Open access
4,870
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation
Ravulizumab for the treatment of myasthenia gravis
Fiammetta Vanolia Neuroimmunology and Neuromuscular Disease Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy;b Department of Human Neurosciences, Sapienza University of Rome, Rome, ItalyView further author information
& Renato Mantegazzaa Neuroimmunology and Neuromuscular Disease Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, ItalyCorrespondence[email protected]
https://orcid.org/0000-0002-9810-5737View further author information
https://orcid.org/0000-0002-9810-5737View further author information
Pages 235-241
|
Received 26 Oct 2022, Accepted 22 Feb 2023, Published online: 08 Mar 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.